

Annual General Meeting – Fresenius SE & Co. KGaA



August 28, 2020

Welcome!



In battle against the coronavirus



Acute care hospitals: a focal point



Ensuring dialysis continues during the pandemic



Maintaining the production and distribution of life-sustaining products



A consistent shift to Mobile Work



Accelerating digitalization across the board



Putting even more “we” in Fresenius




Solid business development despite the pandemic

Sales

in €m

+5%




EBIT

-1%



Net income

-6%



Constant currency growth rates; EBIT and net income before special items

Pandemic puts pressure on share price



Learning the right lessons



Solidarity, not selfishness




2019: A year of investment




16th consecutive record year

Sales (in €bn)




Net income (in €m)



Sales adjusted; net income adjusted and before special items; 2017 adjusted for IFRS 15 adoption; 2017 & 2018 adjusted for divestitures of Care Coordination activities

27th consecutive dividend increase proposed



2019: Proposal

Expanding and advancing home dialysis



New dialysis machine for emerging markets



First biosimilar launched



Investments in production facilities



Challenges in Germany



New business models



Digitalization in the hospitals



Acquisition of Malteser hospitals in Germany



Acquisition of hospital in Albacete, Spain



New proton beam therapy center in Madrid



Additional acquisitions in Colombia



Leading provider of post-acute care



Milestone in project business



Superbly positioned for continued growth



2020 guidance revised to include COVID-19 effects

Sales growth
constant currency

+ 3 to + 6%

Net income growth
constant currency

-4 to + 1%

Before special items, incl. estimated Covid-19-effects

Medium-term goals for 2020-2023 confirmed

Average annual sales growth
organic

+ 4 to + 7%

Average annual earnings growth
organic

+ 5 to + 9%

plus ~1% small to mid-size acquisitions

Before special items

Anchoring sustainability even more firmly in Fresenius



Our commitment: Ever better medicine for ever more people



Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.